Located on the South Side of Chicago, University of Chicago Medicine is an academic medical center on the campus of the University of Chicago, a private research university. The medical center includes Bernard A. Mitchell Hospital, an adult patient facility; Comer Children’s Hospital; Chicago Lying-in Hospital, a maternity and women’s hospital; Duchossois Center for Advanced Medicine, an ambulatory-care facility; the University of Chicago Pritzker School of Medicine, one of the top medical schools in the United States; and affiliated doctors offices and hospitals across the Chicago metro area.
While the University of Chicago was founded in 1892, it took several decades for dreams of a medical campus to be realized. In 1916, the university’s trustees set aside more than $5 million for the construction and endowment of a hospital, but World War I waylaid the process, and it was not completed until 1927. But once the University of Chicago Hospitals was dedicated on Halloween 1927, it wasted no time before expanding. The Home for Destitute and Crippled Children was added in 1928, and the Country Home for Convalescent Children and Chicago Lying-in Hospital were integrated within about a decade.
A tremendous period of growth followed in the 1950s and 1960s with the addition of cancer research centers, research laboratories, a children’s hospital, and other facilities. More recently, University of Chicago has added the Brain Research Pavilion, the Aeromedical Network, the Duchossois Center for Advanced Medicine, and the newest addition, University of Chicago Comer Children’s Hospital.
Since the founding of University of Chicago Medicine, history has been there made time and time again. A University of Chicago doctor discovered a way to preserve blood and established the first civilian blood bank. Sleep research began at the university in the late 1920s, when a doctor established the world’s first sleep laboratory. In the early 1930s, the University of Chicago opened one of the first nurseries for premature infants. Cancer research has also grown immeasurably inside the University of Chicago’s walls; hormone treatments, chemotherapy and genetic links to cancers have all been discovered or advanced by groundbreaking research there.
The University of Chicago Medicine Comprehensive Cancer Center treats patients with a variety of cancers, including malignant mesothelioma. UChicago uses a team-based approach to create personalized treatment plans for each patient.
Mesothelioma treatment at UChicago Medicine may include surgery, chemotherapy, radiation therapy or clinical trials for those who are eligible, with experience with heated intraperitoneal chemotherapy (HIPEC). They are also dedicated to developing and practicing emerging treatment methods to improve patient prognosis. New approaches to chemotherapy, immunotherapy and surgeries have been a primary focus.
The UChicago Medicine Comprehensive Cancer Center understands the struggles that patients and their families have when facing a mesothelioma diagnosis. As a result, they assign each patient with a nurse navigator to offer comprehensive support throughout their treatment journey.
- Emerging treatments
- American Nurses Credentialing Center Magnet Recognition
- Blue Cross and Blue Shield Distinction for Specialty Care
- Cellular therapy accreditation
- Joint Commission full accreditation
- National Cancer Institute Designated Comprehensive Cancer Center
- Top Teaching Hospital
Mesothelioma Clinical Trials at The University of Chicago Medicine Comprehensive Cancer Center
The following clinical trials are in progress or actively recruiting participants at The University of Chicago Medicine Comprehensive Cancer Center:
Conditions: Carcinoma, Melanoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Renal Cell, Mesothelioma, Breast Neoplasms, Lung Neoplasms, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Endometrial Neoplasms, Colorectal Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma, Anus Neoplasms
Last Updated: April 29, 2019
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Conditions: Adenocarcinoma, Sarcoma, Mesothelioma
Last Updated: July 17, 2019
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
Last Updated: September 3, 2019
Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Last Updated: August 20, 2019
Conditions: Carcinoma, Carcinoma, Squamous Cell, Adenocarcinoma, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Breast Neoplasms, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Carcinoma, Basal Cell, Gastrointestinal Stromal Tumors, Carcinoid Tumor, Carcinoma, Transitional Cell, Carcinoma, Adenoid Cystic, Teratoma, Adenocarcinoma of Lung, Carcinoma, Neuroendocrine, Seminoma, Pheochromocytoma, Choriocarcinoma, Cystadenocarcinoma, Cystadenocarcinoma, Serous, Carcinoma, Endometrioid, Chordoma, Paraganglioma, Hemangiosarcoma, Fibromatosis, Aggressive, Trophoblastic Neoplasms, Adenocarcinoma, Mucinous, Gestational Trophoblastic Disease, Adenocarcinoma, Clear Cell, Nerve Sheath Neoplasms, Neurofibrosarcoma, Cystadenocarcinoma, Mucinous, Fibroma, Thyroid Neoplasms, Pseudomyxoma Peritonei, Sex Cord-Gonadal Stromal Tumors, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Vulvar Neoplasms, Paget Disease, Extramammary, Adenocarcinoma, Papillary, Carcinoma, Acinar Cell, Adenocarcinoma, Bronchiolo-Alveolar, Mixed Tumor, Mullerian, Carcinoma, Giant Cell, Neoplasms, Unknown Primary, Neoplasms
Last Updated: September 6, 2019
- Mesothelioma Doctors
- Cancer Centers
- Treatment Near You
- Experimental Treatments
- Alternative Treatments
- Clinical Trials
- Caregiver Resources
- Treatment Costs